Post-transplant bronchiolitis obliterans

European Respiratory Journal

Volumn 22, Issue 6, 2003, Pages 1007-1018

  Boehler, A ^a   Estenne, M ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b ERASME HOSPITAL   (Belgium)

Author keywords

Bronchiolitis obliterans; Chronic allograft dysfunction; Chronic rejection; Lung transplantation

Indexed keywords

ALLOANTIGEN; CANCER GROWTH FACTOR; CD28 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ENDOTHELIN 1; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; PLATELET DERIVED GROWTH FACTOR; SOMATOMEDIN;

ALLOIMMUNITY; BRONCHIOLITIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG TRANSPLANTATION; MORTALITY; NONHUMAN; PATHOGENESIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY OF LIFE; RECIPIENT; REVIEW; RISK ASSESSMENT; SURVIVAL RATE; T LYMPHOCYTE; TH1 CELL; TRANSBRONCHIAL BIOPSY;

EID: 0242473414     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.03.00039103     Document Type: Review

References (144)

1. Hertz MI, Taylor DO, Trulock EP, et al. The Registry of the International Society for Heart and Lung Transplantation: nineteenth official report - 2002. J Heart Lung Transplant 2002; 21: 950-970.
2. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi B. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580-590.
3. Burke CM, Theodore J, Dawkins KD, et al. Post-transplant obliterative bronchiolitis and other late lung sequelae in human heart-lung transplantation. Chest 1984; 86: 824-829.
4. Boehler A, Kesten S, Weder W, Speich R. Bronchiolitis obliterans after lung transplantation. Chest 1998; 114: 1411-1426.
5. Boehler A, Estenne M. Obliterative bronchiolitis after lung transplantation. Curr Opin Pulm Med 2000; 6: 133-139.
6. Estenne M, Hertz MI. Bronchiolitis obliterans after human lung transplantation. Am J Respir Crit Care Med 2002; 166: 440-444.
7. Valentine VG, Robbins RC, Berry GJ, et al. Actuarial survival of heart-lung and bilateral sequential lung transplant recipients with obliterative bronchiolitis. J Heart Lung Transplant 1996; 15: 371-383.
8. Haider Y, Yonan N, Mogulkoc N, Carroll KB, Egan JJ. Bronchiolitis obliterans syndrome in single lung transplant recipients-patients with emphysema versus patients with idiopathic pulmonary fibrosis. J Heart Lung Transplant 2002; 21: 327-333.
9. Stanbrook MB, Kesten S. Bronchial hyperreactivity after lung transplantation predicts early bronchiolitis obliterans. Am J Respir Crit Care Med 1999; 160: 2034-2039.
10. Nathan SD, Ross DJ, Belman MJ, et al. Bronchiolitis obliterans in single-lung transplant recipients. Chest 1995; 107: 967-972.
11. Heng D, Sharples LD, McNeil K, Stewart S, Wreghitt T, Wallwork J. Bronchiolitis obliterans syndrome: Incidence, natural history, prognosis, and risk factors. J Heart Lung Transplant 1998; 17: 1255-1263.
12. Kroshus TJ, Kshettry VR, Savik K, John R, Hertz MI, Bolman RM 3rd. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg 1997; 114: 195-202.
13. Jackson CH, Sharples LD, McNeil K, Stewart S, Wallwork J. Acute and chronic onset of bronchiolitis obliterans syndrome (BOS): are they different entities? J Heart Lung Transplant 2002; 21: 658-666.
14. van den Berg JW, Geertsma A, van der Bij W, et al. Bronchiolitis obliterans syndrome after lung transplantation and health-related quality of life. Am J Respir Crit Care Med 2000; 161: 1937-1941.
15. van den Berg JW, van Enckevort PJ, Ten Vergert EM, Postma DS, van der Bij W, Koeter GH. Bronchiolitis obliterans syndrome and additional costs of lung transplantation, Chest 2000; 118: 1648-1652.
16. Sharples LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant 2002; 21: 271-281.
17. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: An update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297-310.
18. Bando K, Paradis IL, Similo S, et al. Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management. J Thorac Cardiovasc Surg 1995; 110: 4-14.
19. Husain AN, Siddiqui MT, Holmes EW, et al. Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 1999; 159: 829-833.
20. Sharples LD, Tamm M, McNeil K, Higenbottam TW, Stewart S, Wallwork J. Development of bronchiolitis obliterans syndrome in recipients of heart-lung transplantation - early risk factors. Transplantation 1996; 61: 560-566.
21. Girgis RE, Tu I, Berry GJ, et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant 1996; 15: 1200-1208.
22. Ross DJ, Marchevsky A, Kramer M, Kass RM. Refractoriness of airflow obstruction associated with isolated lymphocytic bronchiolitis/bronchitis in pulmonary allografts. J Heart Lung Transplant 1997; 16: 832-838.
23. Kesten S, Maidenberg A, Winton T, Maurer J. Treatment of presumed and proven acute rejection following six months of lung transplant survival. Am J Respir Crit Care Med 1995; 152: 1321-1324.
24. Swanson SJ, Mentzer SJ, Reilly JJ, et al. Surveillance transbronchial lung biopsies: implication for survival after lung transplantation. J Thorac Cardiovasc Surg 2000; 119: 27-37.
25. Lau CL, Palmer SM, Posther KE, et al. Influence of panel-reactive antibodies on posttransplant outcomes in lung transplant recipients. Ann Thorac Surg 2000; 69: 1520-1524.
26. Slebos DJ, Scholma J, Boezen HM, et al. Longitudinal profile of bronchoalveolar lavage cell characteristics in patients with a good outcome after lung transplantation. Am J Respir Crit Care Med 2002; 165: 501-507.
27. Taylor PM, Rose M, Yacoub M. Expression of MHC antigens in normal human lungs and transplanted lungs with obliterative bronchiolitis. Transplantation 1989; 48: 506-510.
28. Milne DS, Gascoigne AD, Wilkes J, et al MHC class II and ICAM-1 expression and lymphocyte subsets in transbronchial biopsies from lung transplant recipients. Transplantation 1994; 57: 1762-1766.
29. Milne DS, Gascoigne A, Wilkes J, et al The immunohistopathology of obliterative bronchiolitis following lung transplantation. Transplantation 1992; 54: 748-750.
30. Devouassoux G, Pison C, Drouet C, Pin I, Brambilla C, Brambilla E. Early lung leukocyte infiltration, HLA and adhesion molecule expression predict chronic rejection. Transplant Immunol 2001; 8: 229-236.
31. Jaramillo A, Smith MA, Phelan D, et al. Development of ELISA-detected anti-HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function after lung transplantation. Transplantation 1999; 67: 1155-1156.
32. Palmer SM, Davis RD, Hadjiliadis D, et al. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation 2002; 74: 799-804.
33. Rabinowich H, Zeevi A, Paradis IL, et al. Proliferative responses of bronchoalveolar lavage lymphocytes from heart-lung transplant patients. Transplantation 1990; 49: 115-121.
34. SivaSai KSR, Smith MA, Poindexter NJ, et al. Indirect recognition of donor HLA Class I peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Transplantation 1999; 67: 1094-1098.
35. Schulman LL, Weinberg AD, McGregor CC, Suciu-Foca NM, Itescu S. Influence of donor and recipient HLA locus mismatching on development of obliterative bronchiolitis after lung transplantation. Am J Respir Crit Care Med 2001; 163: 437-442.
36. Quantz MA, Bennett LE, Meyer DM, Novick RJ. Does human leukocyte antigen matching influence the outcome of lung transplantation? An analysis of 3549 lung transplantations. J Heart Lung Transplant 2000; 19: 473-479.
37. McSherry C, Jackson A, Hertz MI, Bolman III RM, Savik K, Reinsmoen NL. Sequential measurement of peripheral blood allogeneic microchimerism levels and association with pulmonary function. Transplantation 1996; 62: 1811-1818.
38. Duquesnoy R, Zeevi A. Immunological monitoring of lung transplant patients by bronchoalveolar analysis. Transplant Rev 1992; 6: 218-230.
39. De Haan A, van der Gun I, Hepkema BG, et al. Decreased donor-specific cytotoxic T cell precursor frequencies one year after clinical lung transplantation do not reflect transplantation tolerance: a comparison of lung transplant recipients with or without bronchiolitis obliterans syndrome. Transplantation 2000; 69: 1434-1439.
40. Pham SM, Rao AS, Zeevi A, et al. Effects of donor bone marrow infusion in clinical lung transplantation. Ann Thorac Surg 2000; 69: 345-350.
41. Chaparro C, Maurer JR, Chamberlain D, et al Causes of death in lung transplant recipients. J Heart Lung Transplant 1994; 13: 758-766.
42. Cahill BC, Hibbs JR, Savik K, et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest 1997; 112: 1160-1164.
43. Grossi P, Farina C, Fiocchi R, Dalla Gasperina D. Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: a multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients. Transplantation 2000; 70: 112-116.
44. Zamora MR. Controversies in lung transplantation: management of cytomegalovirus infections. J Heart Lung Transplant 2002; 21: 841-849.
45. Speich R, Thurnheer R, Gaspert A, Weder W, Boehler A. Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation. Transplantation 1999; 67: 315-320.
46. Duncan SR, Grgurich WF, Iacono AT, et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med 1994; 150: 146-152.
47. Soghikian MV, Valentine VG, Berry GJ, Patel HR, Robbins RC, Theodore J. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients. J Heart Lung Transplant 1996; 15: 881-887.
48. Billings JL, Hertz MI, Wendt CH. Community respiratory virus infections following lung transplantation. Transpl Infect Dis 2001; 3: 138-148.
49. Vilchez RA, McCurry K, Dauber J, et al. The epidemiology of parainfluenza virus infection in lung transplant recipients. Clin Infect Dis 2001; 33: 2004-2008.
50. Norgaard MA, Andersen CB, Pettersson G. Does bronchial artery revascularization influence results concerning bronchiolitis obliterans syndrome and/or obliterative bronchiolitis after lung transplantation. Eur J Cardiothorac Surg 1998; 14: 311-318.
51. Novick RJ, Bennett LE, Meyer DM, Hosenpud JD. Influence of graft ischemic time and donor age on survival after lung transplantation. J Heart Lung Transplant 1999; 18: 425-431.
52. Hadjiliadis D, Davis RD, Lawrence CM, et al. Association of bronchiolitis obliterans syndrome (BOS) with gastroesophageal reflux disease (GERD) in lung transplant recipients. Am J Respir Crit Care Med 2001; 163: A325.
53. Palmer SM, Hadjiiliadis D, Eubanks WS, et al. Impact of early fundoplication surgery on pulmonary function in lung transplant recipients with gastroesophageal reflux. Am J Respir Crit Care Med 2001; 163: A325.
54. Lau CL, Palmer SM, Hadjiliadis D, Pappas TN, Eubanks WS, Davis RD. Anti-reflux surgery improves pulmonary function in lung transplant patients. J Heart Lung Transplant 2002; 21: 108.
55. Friedman A. Strategies to improve outcomes after renal transplantation. N Engl J Med 2002; 346: 2089-2092.
56. Chisholm MA, Vollenweider LJ, Mulloy LL, et al. Renal transplant patient compliance with free immunosuppressive medications. Transplantation 2000; 70: 1240-1244.
57. Awad M, Pravica V, Perrey C, et al. CA repeat allele polymorphism in the first intron of the human interferon-gamma gene is associated with lung allograft fibrosis. Hum Immunol 1999; 60: 343-346.
58. El-Gamel A, Awad MR, Hasleton PS, et al. Transforming growth factor-beta (TGF-beta1) genotype and lung allograft fibrosis. J Heart Lung Transplant 1999; 18: 517-523.
59. Yousem SA, Berry GJ, Cagle PT, et al Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung rejection study group. J Heart Lung Transplant 1996; 15: 1-15.
60. Halloran PF, Homik J, Goes N, et al. The "injury response": a concept linking nonspecific injury, acute rejection, and long-term transplant outcomes. Transplant Proc 1997; 29: 79-81.
61. Marck KW, Wildevuur CR. Lung transplantation in the rat: I. Technique and survival. Ann Thorac Surg 1982; 34: 74-80.
62. Al-Dossari GA, Kshettry VR, Jessurun J, Bolman RM 3rd. Experimental large-animal model of obliterative bronchiolitis after lung transplantation. Ann Thorac Surg 1994; 58: 34-40.
63. Yasufuku K, Heidler KM, Woods KA, et al. Prevention of bronchiolitis obliterans in rat lung allografts by type V collagen-induced oral tolerance. Transplantation 2002; 73: 500-505.
64. Hirt SW, You XM, Moller F, et al. Development of obliterative bronchiolitis after allogeneic rat lung transplantation: implication of acute rejection and the time point of treatment. J Heart Lung Transplant 1999; 18: 542-548.
65. Hertz MI, Jessurun J, King MB, Savik SK, Murray JJ. Reproduction of the obliterative bronchiolitis lesion after heterotopic transplantation of mouse airways. Am J Pathol 1993; 142: 1945-1951.
66. Davreux CJ, Chu NH, Waddell TK, Mayer E, Patterson GA. Improved tracheal allograft viability in immunosuppressed rats. Ann Thorac Surg 1993; 55: 131-134.
67. Huang XH, Reichenspurner H, Shorthouse R, Cao W, Berry G, Morris R. Heterotopic tracheal allograft transplantation: a new model to study the molecular events causing obliterative airway disease in rats. J Heart Lung Transplant 1995; 14: S49.
68. Hele DJ, Yacoub MH, Belvisi MG. The heterotopic tracheal allograft as an animal model of obliterative bronchiolitis. Respir Res 2001; 2: 169-183.
69. Boehler A, Chamberlain D, Kesten S, Slutsky AS, Liu M, Keshavjee S. Lymphocytic airway infiltration as a precursor to fibrous obliteration in a rat model of bronchiolitis obliterans. Transplantation 1997; 64: 311-317.
70. Adams BF, Brazelton T, Berry GJ, Morris RE. The role of respiratory epithelium in a rat model of obliterative airway disease. Transplantation 2000; 69: 661-664.
71. Adams BF, Brazelton T, Lange E, Huang X, Morris RE. Airway epithelial cells prevent obliterative airway disease (OAD) in heterotopically transplanted rat tracheal grafts. J Heart Lung Transplant 1998; 17: 47.
72. Rumbley CA, Silver SJ, Phillips SM. Dependence of murine obstructive airway disease on CD40 ligand. Transplantation 2001; 72: 1616-1625.
73. Neuringer I, Mannon RB, Coffman TM, et al. Immune cells in a mouse airway model of obliterative bronchiolitis. Am J Respir Cell Mol Biol 1998; 19: 379-386.
74. Belperio JA, Keane MP, Burdick MD, et al. Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome. J Immunol 2002; 169: 1037-1049.
75. Szeto WY, Krasinskas AM, Kreisel D, Popma SH, Rosengard BR. Donor antigen-presenting cells are important in the development of obliterative airway disease. J Thorac Cardiovasc Surg 2000; 120: 1070-1077.
76. Smith MA, Jaramillo A, Sivasai KSR, et al. Indirect recognition and antibody production against a single mismatched HLA-A2-transgenic molecule precede the development of obliterative airway disease in murine heterotopic tracheal allografts. Transplantation 2002; 73: 186-193.
77. Tikkanen JM, Lemström KB, Koskinen PK. Blockade of CD28/B7-2 costimulation inhibits experimental obliterative bronchiolitis in rat tracheal allografts: suppression of helper T cell type1-dominated immune response. Am J Respir Crit Care Med 2002; 165: 724-729.
78. Konishi K, Inobe M, Yamada A, Murakami M, Todo S, Uede T. Combination treatment with FTY720 and CTLA4IgG preserves the respiratory epithelium and prevents obliterative disease in a murine airway model. J Heart Lung Transplant 2002; 21: 692-700.
79. Neuringer IP, Walsh SP, Mannon RB, Gabriel S, Aris RM. Enhanced T cell cytokine gene expression in mouse airway obliterative bronchiolitis. Transplantation 2000; 69: 399-405.
80. Boehler A, Bai XH, Liu M, et al. Upregulation of T-helper 1 cytokines and chemokine expression in post-transplant airway obliteration. Am J Respir Crit Care Med 1999; 159: 1910-1917.
81. Suga M, Maclean AA, Keshavjee S, Fischer S, Moreira JM, Liu M. RANTES plays an important role in the evolution of allograft transplant-induced fibrous airway obliteration. Am J Respir Crit Care Med 2000; 162: 1940-1948.
82. Belperio JA, Keane MP, Burdick MD, et al. Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. J Clin Invest 2001; 108: 547-556.
83. Alho HS, Inkinen KA, Salminen U-S, et al. Collagens I and III in a porcine bronchial model of obliterative bronchiolitis. Am J Respir Crit Care Med 2001; 164: 1519-1525.
84. Aris RM, Walsh S, Chalermskulrat W, Hathwar V, Neuringer IP. Growth factor upregulation during obliterative bronchiolitis in the mouse model. Am J Respir Crit Care Med 2002; 166: 417-422.
85. Tikkanen JM, Kallio EA, Bruggeman CA, Koskinen PK, Lemstrom KB. Prevention of cytomegalovirus infection-enhanced experimental obliterative bronchiolitis by antiviral prophylaxis or immunosuppression in rat tracheal allografts. Am J Respir Crit Care Med 2001; 164: 672-679.
86. Boehler A, Chamberlain D, Xing Z, et al. Adenoviral-mediated IL-10 gene transfer inhibits post-transplant fibrous airway obliteration in an animal model of bronchiolitis obliterans. Hum Gene Ther 1998; 9: 541-551.
87. Roth-Eichhorn S, Schade I, Kasper M, et al. Anti-proliferative properties of the phosphodiesterase-4 inhibitor rolipram can supplement immunosuppressive effects of cyclosporine for treatment of obliterative bronchiolitis in heterotopic rat allografts. J Heart Lung Transplant 2001; 20: 1188-1198.
88. Fahrni JA, Berry GJ, Morris RE, Rosen GD. Rapamycin inhibits development of obliterative airway disease in a murine heterotropic airway transplant model. Transplantation 1997; 63: 533-537.
89. Koskinen PK, Kallio EA, Krebs R, Lemstrom KB. A dose-dependent inhibitory effect of cyclosporine A on obliterative bronchiolitis of rat tracheal allografts. Am J Respir Crit Care Med 1997; 155: 303-312.
90. Morris RE, Huang X, Gregory CR, et al. Studies in experimental models of chronic rejection: Use of rapamycin (Sirolimus) and isoxazole derivatives (Leflunomide and its analogue) for the suppression of graft vascular disease and obliterative bronchiolitis. Transplant Proc 1995; 27: 2068-2069.
91. Maclean AA, Liu M, Fischer S, Suga M, Keshavjee S. Targeting the angiotensin system in posttransplant airway obliteration: the antifibrotic effect of angiotensin converting enzyme inhibition. Am J Respir Crit Care Med 2000; 162: 310-315.
92. Kallio EA, Lemström KB, Häyry PJ, Ryan US, Koskinen PK. Blockade of complement inhibits obliterative bronchiolitis in rat tracheal allografts. Am J Respir Crit Care Med 2000; 161: 1332-1339.
93. Reznik SI, Jaramillo A, Zhang L, Patterson GA, Cooper JD, Mohanakumar T. Anti-HLA antibody binding to HLA class I molecules induces proliferation of airway epithelial cells: a potential mechanism for bronchiolitis obliterans syndrome. J Thorac Cardiovasc Surg 2000; 119: 39-45.
94. Jaramillo A, Naziruddin B, Zhang L, et al. Activation of human airway epithelial cells by non-HLA antibodies developed after lung transplantation: a potential etiological factor for bronchiolitis obliterans syndrome. Transplantation 2001; 71: 966-976.
95. Elssner A, Jaumann F, Wolf W-P, et al. Bronchial epithelial cell B7-1 and B7-2 mRNA expression after lung transplantation: a role in allograft rejection. Eur Respir J 2002; 20: 165-169.
96. Nord M, Schubert K, Cassel TN, Andersson O, Riise GC. Decreased serum and bronchoalveolar lavage levels of clara cell secretory protein (CC16) is associated with bronchiolitis obliterans syndrome and airway neutrophilia in lung transplant recipients. Transplantation 2002; 73: 1264-1269.
97. Leonard CT, Soccal PM, Singer L, et al. Dendritic cells and macrophages in lung allografts: a role in chronic rejection. Am J Respir Crit Care Med 2000; 161: 1349-1354.
98. Yousem SA, Ray L, Paradis IL, Dauber JA, Griffith BP. Potential role of dendritic cells in bronchiolitis obliterans in heart-lung transplantation. Ann Thorac Surg 1990; 49: 424-428.
99. Scholma J, Slebos D-J, Boezen HM, et al. Eosinophilic granulocytes and interleukin-6 level in bronchoalveolar lavage fluid are associated with the development of obliterative bronchiolitis after lung transplantation. Am J Respir Crit Care Med 2000; 162: 2221-2225.
100. Reynaud-Gaubert M, Thomas P, Badier M, Can P, Giudicelli R, Fuentes P. Early detection of airway involvement in obliterative bronchiolitis after lung transplantation. Functional and bronchoalveolar lavage cell findings. Am J Respir Crit Care Med 2000; 161: 1924-1929.
101. Zheng L, Walters EH, Ward C, et al. Airway neutrophilia in stable and BOS patients following lung transplantation. Thorax 2000; 55: 53-59.
102. Reynaud-Gaubert M, Marin V, Thirion X, et al. Upregulation of chemokines in bronchoalveolar lavage fluid as a predictive marker of post-transplant airway obliteration. J Heart Lung Transplant 2002; 21: 721-730.
103. Snell GI, Ward C, Wilson JW, Orsida B, Williams TJ, Walters EH. Immunopathological changes in the airways of stable lung transplant recipients. Thorax 1997; 52: 322-328.
104. Ward C, Whitford H, Snell G, et al. Bronchoalveolar lavage macrophage and lymphocyte phenotypes in lung transplant recipients. J Heart Lung Transplant 2001; 20: 1064-1074.
105. Beeh KM, Kornmann O, Lill J, Buhl R. Induced sputum cell profiles in lung transplant recipients with or without chronic rejection: correlation with lung function. Thorax 2001; 56: 557-560.
106. Elssner A, Vogelmeier C. The role of neutrophils in the pathogenesis of obliterative bronchiolitis after lung transplantation. Transpl Infect Dis 2001; 3: 168-176.
107. Riise GC, Andersson BA, Kjellstrom C, et al. Persistent high BAL fluid granulocyte activation marker levels as early indicators of bronchiolitis obliterans after lung transplant. Eur Respir J 1999; 14: 1123-1130.
108. Riise GC, Williams A, Kjellstrom C, Schersten H, Andersson BA, Kelly FJ. Bronchiolitis obliterans syndrome in lung transplant recipients is associated with increased neutrophil activity and decreased antioxidant status in the lung. Eur Respir J 1998; 12: 82-88.
109. Hirsch J, Elssner A, Mazur G, et al. Bronchiolitis obliterans syndrome after heart-lung transplantation. Impaired anti-protease defense and increased oxidant activity. Am J Respir Crit Care Med 1999; 160: 1640-1646.
110. Behr J, Maier K, Braun B, Schwaiblmair M, Vogelmeier C. Evidence for oxidative stress in bronchiolitis obliterans syndrome after lung and heart-lung transplantation. Transplantation 2000; 69: 1856-1860.
111. Meyer KC, Nunley DR, Dauber JH, et al. Neutrophils, unopposed neutrophil elastase, and alpha 1-antiprotease defenses following human lung transplantation. Am J Respir Crit Care Med 2001; 164: 97-102.
112. Williams A, Riise GC, Anderson BA, Kjellstrom C, Schersten H, Kelly FJ. Compromised antioxidant status and persistent oxidative stress in lung transplant recipients. Free Radic Res 1999; 30: 383-393.
113. Reid D, Snell G, Ward C, et al. Iron overload and nitric oxide-derived oxidative stress following lung transplantation. J Heart Lung Transplant 2001; 20: 840-849.
114. Dai H, Xie C, Churg A. Iron loading makes a nonfibrogenic model air pollutant particle fibrogenic in rat tracheal explants. Am J Respir Cell Mol Biol 2002; 26: 685-693.
115. Elssner A, Jaumann F, Dobmann S, et al. Elevated levels of interleukin-8 and transforming growth factor-beta in bronchoalveolar lavage fluid from patients with bronchiolitis obliterans syndrome: proinflammatory role of bronchial epithelial cells. Transplantation 2000; 70: 362-367.
116. DiGiovine B, Lynch JP III, Martinez FJ, et al. Bronchoalveolar lavage neutrophilia is associated with obliterative bronchiolitis after lung transplantation: role of IL-8. J Immunol 1996; 157: 4194-4202.
117. Charpin J-M, Stern M, Lebrun G, Aubin P, Grenet D, Israel-Biet D. Increased endothelin-1 associated with bacterial infection in lung transplant recipients. Transplantation 2001; 71: 1840-1847.
118. Hertz MI, Henke CA, Nakhleh RE, et al. Obliterative bronchiolitis after lung transplantation: A fibroproliferative disorder associated with platelet-derived growth factor. Proc Natl Acad Sci USA 1992; 89: 10385-10389.
119. Charpin J-M, Stern M, Grenet D, Israel-Biet D. Insulin-like growth factor-1 in lung transplants with obliterative bronchiolitis. Am J Respir Crit Care Med 2000; 161: 1991-1998.
120. El-Gamel A, Sim E, Hasleton P, et al. Transforming growth factor beta (TGF-beta) and obliterative bronchiolitis following pulmonary transplantation. J Heart Lung Transplant 1999; 18: 828-837.
121. Magnan A, Mege JL, Escallier JC, et al. Balance between alveolar macrophage IL-6 and TGF-beta in lung-transplant recipients. Marseille and Montreal Lung Transplantation Group. Am J Respir Crit Care Med 1996; 153: 1431-1436.
122. Charpin JM, Valcke J, Kettaneh L, Epardeau B, Stern M, Israel-Biet D. Peaks of transforming growth factor-beta mRNA in alveolar cells of lung transplant recipients as an early marker of chronic rejection. Transplantation 1998; 65: 752-755.
123. Jonosono M, Fang KC, Keith FM, et al. Measurement of fibroblast proliferative activity in bronchoalveolar lavage fluid in the analysis of obliterative bronchiolitis among lung transplant recipients. J Heart Lung Transplant 1999; 18: 972-985.
124. Cooper J, Billingham M, Egan T, et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J Heart Lung Transplant 1993; 12: 713-716.
125. Estenne M, van Muylem A, Knoop C, Antoine M. Detection of obliterative bronchiolitis by indexes of ventilation distribution. Am J Respir Crit Care Med 2000; 162: 1047-1051.
126. Ouwens JP, van der Mark TW, Koeter GH, de Boer WJ, Grevink RG, van der Bij W. Bronchiolar airflow impairment after lung transplantation: an early and common manifestation. J Heart Lung Transplant 2002; 21: 1056-1061.
127. Moy ML, Loring SH, Ingenito EP, Mentzer SJ, Reilly JJ Jr. Causes of allograft dysfunction after single lung transplantation for emphysema: extrinsic restriction versus intrinsic obstruction. Brigham and Women's Hospital Lung Transplantation Group. J Heart Lung Transplant 1999; 18: 986-993.
128. Nathan SD, Wolhrab J, Barnett SD. Retrospective validation of BOS 0-p as a predictor of BOS in single lung transplant recipients. J Heart Lung Transplant 2002; 21: 76.
129. McGiffin DC. Classification of bronchiolitis obliterans syndrome-taxonomic realism or skepticism. J Heart Lung Transplant 2002; 21: 941-944.
130. Boehler A, Vogt P, Zollinger A, Weder W, Speich R. Prospective study of the value of regular transbronchial lung biopsy in the management of lung transplant recipients. Eur Respir J 1996; 9: 658-662.
131. Trulock EP, Ettinger NA, Brunt EM, Pasque MK, Kaiser LR, Cooper JD. The role of transbronchial lung biopsy in the treatment of lung transplant recipients. An analysis of 200 consecutive procedures. Chest 1992; 102: 1049-1054.
132. Morlion B, Knoop C, Paiva M, Estenne M. Internet-based home monitoring of pulmonary function after lung transplantation. Am J Respir Crit Care Med 2002; 165: 694-697.
133. Finkelstein SM, Snyder M, Stibbe CE, et al. Staging of bronchiolitis obliterans syndrome using home spirometry. Chest 1999; 116: 120-126.
134. van Muylem A, Paiva M, Estenne M. Involvement of peripheral airways during methacholine-induced bronchoconstriction after lung transplantation. Am J Respir Crit Care Med 2001; 164: 1200-1203.
135. Beeh KM, Beier J, Kornmann O, Micke P, Buhl R. Sputum levels of metalloproteinase-9 and tissue inhibitor of metalloproteinase-1, and their ratio correlate with airway obstruction in lung transplant recipients: relation to tumor necrosis factor-alpha and interleukin-10. J Heart Lung Transplant 2001; 20: 1144-1151.
136. Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1693-1722.
137. Studer SM, Orens JB, Rosas I, et al. Patterns and significance of exhaled-breath biomarkers in lung transplant recipients with acute allograft rejection. J Heart Lung Transplant 2001; 20: 1158-1166.
138. Hofer M, Rechsteiner T, Becher G, et al. Leukotriene B4 in exhaled breath condensate of patients after lung transplantation. Eur Respir J 2001; 18: Suppl. 33, 297s.
139. Gabbay E, Walters EH, Orsida B, et al. Post-lung transplant bronchiolitis obliterans syndrome (BOS) is characterized by increased exhaled nitric oxide levels and epithelial inducible nitric oxide synthase. Am J Respir Crit Care Med 2000; 162: 2182-2187.
140. Silkoff PE, Caramori M, Tremblay L, et al. Exhaled nitric oxide in human lung transplantation. A noninvasive marker of acute rejection. Am J Respir Crit Care Med 1998; 157: 1822-1828.
141. Fisher AJ, Gabbay E, Small T, Doig S, Dark JH, Corris PA. Cross sectional study of exhaled nitric oxide levels following lung transplantation. Thorax 1998; 53: 454-458.
142. De Soyza A, Fisher AJ, Small T, Corris PA. Inhaled corticosteroids and the treatment of lymphocytic bronchiolitis following lung transplantation. Am J Respir Crit Care Med 2001; 164: 1209-1212.
143. Bankier AA, Muylem AV, Knoop C, Estenne M, Gevenois PA. Bronchiolitis obliterans syndrome in heart-lung transplant recipients: Diagnosis with expiratory CT. Radiology 2001; 218: 533-539.
144. Lee E-S, Gotway MB, Reddy GP, Golden JA, Keith FM, Webb WR. Early bronchiolitis obliterans following lung transplantation. Radiology 2000; 216: 472-477.